Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Kam Dhaliwal, SVP Strategic Alliances & Dr Thomas Moreau, Head of Research. 2020. bit.bio talk at ELRIG

Listen to our talk at the recent ELRIG conference and learn how bit.bio’s opti-ox™ can generate cells with high consistency and functionality at scale from human iPSCs, including those carrying disease-specific mutations, providing high-quality human models for enhanced research outcomes and drug discovery efficiency.